nach oben

20.04.2024 | Original Article

Efficacy and safety of proton pump inhibitors on cardiovascular events and inflammatory factors in patients with upper gastrointestinal bleeding undergoing dual antiplatelet therapy

verfasst von: Shuting Yang, Linni Shi

Einloggen, um Zugang zu erhalten

Abstract

Background

This work evaluated the effects of proton pump inhibitors (PPIs) on cardiovascular events (CVEs) and inflammatory factors in patients with upper gastrointestinal bleeding (UGIB) undergoing dual antiplatelet therapy (DAPT) after percutaneous coronary intervention. Clinical data from these patients were analysis, intending to provide relevant theoretical evidence for clinical practice.

Materials and methods

Data of 166 patients who underwent percutaneous coronary intervention and developed UGIB while on DAPT at The First People’ Hospital of Linping District from April 2021 to April 2023 were retrospectively analyzed. The patients were rolled into two groups: those who received PPI treatment and those who did not, namely, PPI and non-PPI group, respectively. Furthermore, occurrence of CVEs and the levels of inflammatory factors of patients in all groups were statistically analyzed.

Results

In patients with UGIB, melena is a common presentation. The incidence of CVE in the PPI group showed no statistically significant difference compared to the control group, and there was no significant variance observed in the distribution of CVE incidence among different PPIs. However, levels of C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α) were significantly lower in the PPI group compared to the non-PPI group (P < 0.05).

Conclusion

Melena was the most frequent clinical manifestation in UGIB patients. The use of PPIs did not increase the risk of CVEs, and different PPI drugs did not affect the occurrence of CVEs. Furthermore, PPIs lowered CRP and TNF-α levels in serum of these patients.

Andò G, De Santis GA, Greco A, Pistelli L, Francaviglia B, Capodanno D, Caterina RD, Capranzano P (2022) P2Y12 inhibitor or aspirin following dual antiplatelet therapy after percutaneous coronary intervention: a network meta-analysis. JACC Cardiovasc Interv 15(22):2239–2249CrossRefPubMed

Chen XF, Lin HT, Huang CL (2022) Triptonide restore cisplatin sensitivity in drug-resistant gastric cancer cells by inhibiting protective autophagy. J Biol Regul Homeost Agents 36(6):1887–1896

Ciardullo S, Rea F, Savaré L, Morabito G, Perseghin G, Corrao G (2022) Prolonged use of proton pump inhibitors and risk of type 2 diabetes: results from a large population-based nested case-control study. J Clin Endocrinol Metab 107(7):E2671–E2679CrossRefPubMedPubMedCentral

Cui Y (2023) Clinical efficacy analysis of nutritional support therapy combined with conventional regimen in the treatment of upper gastrointestinal bleeding in patients with liver cirrhosis [J]. Chin Foreign Med J 42(30):52–55

Dharmarajan TS (2021) The use and misuse of proton pump inhibitors: an opportunity for deprescribing. J Am Med Dir Assoc 22(1):15–22CrossRefPubMed

Ha ACT, Bhatt DL, Rutka JT, Johnston SC, Mazer CD, Verma S (2021) Intracranial hemorrhage during dual antiplatelet therapy: JACC review topic of the week. J Am Cardiol 78(13):1372–1384CrossRef

Hopkins AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, Logan JM, Badaoui S, Karapetis CS, Rowland A, Sorich MJ (2022) Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer 126(1):42–47CrossRefPubMed

Ma Z, Zhao W, Wang P (2024) The effects of different proton pump inhibitors on gastrointestinal hormones and oxidative stress in patients with gastric ulcers [J]. Guizhou Med J 48(01):55–56

Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Bleve S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F (2022) Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma. Target Oncol 17(1):61–68CrossRefPubMed

Pan D, Ip A, Zhan S, Wasserman I, Snyder DJ, Agathis AZ, Shamapant N, Yang JY, Pai A, Mazumdar M, Poor H (2021) Pre-hospital antiplatelet medication use on COVID-19 disease severity. Heart Lung 50(5):618–621CrossRefPubMedPubMedCentral

Salvo EM, Ferko NC, Cash SB, Gonzalez A, Kahrilas PJ (2021) Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment PharmacolTher 54(2):129–143CrossRef

Scudiero F, Canonico ME, Sanna GD, Dossi F, Silverio A, Galasso G, Esposito G, Porto I, Parodi G (2022) Dual antiplatelet therapy with 3rd generation p2y12 inhibitors in stemi patients: impact of body mass index on loading dose–response. Cardiovasc Drugs Ther 37(4):695–703CrossRefPubMed

Shadhin KA, Hasan MR, Paul BK, Ahmed K, Moni MA, Kahrizi D, Bhuyian T, Ibrahim SM (2020) Analysis of topological properties and drug discovery for bipolar disorder and associated diseases: a bioinformatics approach. Cell Mol Biol 66(7):152–160CrossRefPubMed

Shang MG, Zhang LL, Chen XH, Zheng SS (2019) Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis. Discov Med 28(153):159–172PubMed

Tang ML, Li HD, Ning JF, Shen XY, Sun X (2022) Discovery of first-in-class tak1–mkk3 protein–protein interaction (ppi) inhibitor (r)-stu104 for the treatment of ulcerative colitis through modulating tnf-α production. J Med Chem 65(9):6690–6709CrossRefPubMed

Wang YF, Ruan CL, Chen SJ, Pei TB, Liu ZY, Wang L, Wang SH, Du HR (2019) Influences of dual antiplatelet therapy on neurological function, hemorheology and outcomes in patients with posterior circulation ischemic stroke. Acta Medica Mediterr 35(2):871–876

Wang X, Zhang R, Wang S, Gu MJ, Li Y, Zhuang XP, Chen C, Yang PM, Guo GL, Sun P (2023) Development, characterisation, and in vitro anti-tumor effect of self-microemulsifying drug delivery system containing polyphyllin I. Drug Deliv Transl Res 13(1):356–370CrossRefPubMed

Wu PX, Liang SF, He YP, Lv R, Yang BD, Wang M, Wang C, Li Y, Song XH, Sun WL (2022) Network pharmacology analysis to explore mechanism of three flower tea against nonalcoholic fatty liver disease with experimental support using high-fat diet-induced rats. Chin Herb Med 14(2):273–282PubMedPubMedCentral

Xy Hu, Cx L, My Z, Zhang Wh (2022) Impact of the PEAR 1 polymorphism on clinical outcomes in Chinese patients receiving dual antiplatelet therapy after percutaneous coronary intervention. Pharmacogenomics 23(11):639–648CrossRef

Yang J, Li F, Xie Y, Mu Y, Han R, Wang M, Gao X (2023) Study on the correlation between nutritional index and severity of upper gastrointestinal bleeding in patients with liver cirrhosis and short-term prognosis [J]. Shaanxi Med J 52(11):1530–1534

Zhang H, Bai R, Bao L, Zhang X, Sun L, Ma M, Cheng Z, Chen A, Wang Y (2021) Proton pump inhibitors induce vascular endothelial inflammation by activating calcineurin [J]. J Nanjing Med Univ (nat Sci Ed) 41(02):173–180

Zhou JD, Wang XS, Lee SR, Wu WKK, Cheung BMY, Zhang QP, Tse G (2021) Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study. Gut 70(10):2012–2013CrossRefPubMed

Benenati S, Galli M, De Marzo V, Pescetelli F, Toma M, Andreotti F, Bona RD, Canepa M, Ameri P, Crea F, Porto I (2021) Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. Eur Heart J-Cardiovascr Pharmacother 7(2):86–93

Chong B, Goh RSJ, Kong G, Sim FRE, Ng CH, Teo XYV, Quek JK, Lim O, Chin YH, Chan SP, Chan MY, Tan HC, Chew NWS, Loh PH (2022) Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients. J Thromb Thrombolysis 53(3):671–682

Giacoppo D, Matsuda Y, Fovino LN, D’Amico G, Gargiulo G, Byrne RA, Capodanno D, Valgimigli M, Mehran R, Tarantini G (2021) Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 42(4):308–319

Ku JC, Taslimi S, Zuccato J, Pasarikovski CR, Nasr N, Chechik O, Chisci E, Bissacco D, Larrue V, Rabinovich Y, Michelagnoli S, Settembrini PG, Priola SM, Cusimano MD, Yang VXD, Macdonald RL (2022) Editor’s choice-peri-operative outcomes of carotid endarterectomy are not improved on dual antiplatelet therapy vs. aspirin monotherapy: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 63(4):546–555

Marcaccio CL, Patel PB, Liang P, Rastogi V, Stangenberg L, Jim J, Schneider PA, Schermerhorn ML (2022) Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting. J Vasc Surg 75(4):1293–1303

Montalto C, Costa F, Leonardi S, Micari A, Oreglia JA, Vranckx P, Capodanno D, Berg J, Lopes RD, Valgimigli M (2023) Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. Eur Heart J-Cardiovascr Pharmacother 9(3):220–230

Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Montagna ES, Ungaro V, Lorusso M, Palmiotti G (2022) Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: a systematic review and meta-analysis. Cancers 14(6):1404(1–12)

Tong S, Kaitu’u-Lino TJ, Hastie R, Brownfoot F, Cluver C, Hannan N (2022) Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. Am J Obstet Gynecol 226(2):S1157–S1170

Tsigkas G, Vakka A, Apostolos A, Bousoula E, Vythoulkas BN, Koufou EE, Vasilagkos G, Tsiafoutis I, Hamilos M, Aminian A, Davlouros P (2023) Dual Antiplatelet therapy and cancer; balancing between ischemic and bleeding risk: a narrative review. J Cardiovasc Dev Dis 10(4):135(1–16)

Yen EF, Amusin DB, Yoo J, Ture A, Gentile NM, Goldberg MJ, Goldstein JL (2022) Nonsteroidal anti-inflammatory drug exposure and the risk of microscopic colitis. BMC Gastroenterol 22(1):367(1–8)

Zhou MG, Zhang J, Liu J, Smith SC, Ma CS, Ge J, Huo Y, Fonarow GC, Liu J, Hao YCH, Gao F, Sun YM, Morgan L, Yang N, Hu GL, Zeng YH, Han YL, Zhao D, CCC-ACS Investigators (2022) Proton pump inhibitors and in-hospital gastrointestinal bleeding in patients with acute coronary syndrome receiving dual antiplatelet therapy. Mayo Clin Proc 97(4):682–692

Zhu DM, Zhang TF, Li Y, Huang CY, Suo M, Xia LG, Xu YH, Li GX, Tang BZ (2022) Tumor-derived exosomes co-delivering aggregation-induced emission luminogens and proton pump inhibitors for tumor glutamine starvation therapy and enhanced type-I photodynamic therapy. Biomaterials 283:121462(1–8)

Titel: Efficacy and safety of proton pump inhibitors on cardiovascular events and inflammatory factors in patients with upper gastrointestinal bleeding undergoing dual antiplatelet therapy
verfasst von: Shuting Yang
Linni Shi
Publikationsdatum: 20.04.2024
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-024-01467-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Efficacy and safety of proton pump inhibitors on cardiovascular events and inflammatory factors in patients with upper gastrointestinal bleeding undergoing dual antiplatelet therapy

Abstract

Background

Materials and methods

Results

Conclusion

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten